These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 31948541)

  • 1. [Erratum: Current Status and Progress in Molecular Imaging of Non-small Cell Lung Cancer for Molecular Targeted EGFR-TKI Treatment Sensitivity and Treatment Tolerance Prediction].
    Editorial Office of Chinese Journal of Lung Cancer
    Zhongguo Fei Ai Za Zhi; 2020 Jan; 23(1):49. PubMed ID: 31948541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Erratum: Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)].
    Editorial Office of Chinese Journal of Lung Cancer
    Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):210. PubMed ID: 32209187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Erratum: Emerging Actions of Pterostilbene on Cancer Research].
    Editorial Office of Chinese Journal of Lung Cancer
    Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):195. PubMed ID: 32209186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current Status and Progress in Molecular Imaging of Non-small Cell Lung 
Cancer for Molecular Targeted EGFR-TKI Treatment Sensitivity and 
Treatment Tolerance Prediction].
    Dai D; Xu W; Wang Q; Li X; Zhu Y
    Zhongguo Fei Ai Za Zhi; 2017 Dec; 20(12):852-856. PubMed ID: 29277186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retraction of "Effect of bufalin on proliferation and apoptosis of human non-small cell lung cancer A549 Cell. Zhongguo Fei Ai Za Zhi, 2010, 13(9): 841-845".
    Zhongguo Fei Ai Za Zhi; 2010 Nov; 13(11):1045. PubMed ID: 21081045
    [No Abstract]   [Full Text] [Related]  

  • 6. Retraction of " Lung cancer: microRNA and target database. Zhongguo Fei Ai Za Zhi, 2012, 15(7): 429-434".
    Kiran C; Deepika P
    Zhongguo Fei Ai Za Zhi; 2012 Aug; 15(8):470. PubMed ID: 22901994
    [No Abstract]   [Full Text] [Related]  

  • 7. [Retraction of "Altered Treg and IL-1A Expression in the Immune Microenvironment of Lung Squamous-cell Cancer after EGFR Blockade. Zhongguo Feiai Zazhi, 2017, 20(3): 143-148."].
    Editorial Office of Chinese Journal of Lung Cancer
    Zhongguo Fei Ai Za Zhi; 2023 Jun; 26(6):448. PubMed ID: 37488086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.
    Balko JM; Potti A; Saunders C; Stromberg A; Haura EB; Black EP
    BMC Genomics; 2006 Nov; 7():289. PubMed ID: 17096850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
    Li Y; Zhang FS; Guo L; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
    [No Abstract]   [Full Text] [Related]  

  • 10. Strategies to Improve Outcomes of Patients with EGRF-Mutant Non-Small Cell Lung Cancer: Review of the Literature.
    Zhou C; Yao LD
    J Thorac Oncol; 2016 Feb; 11(2):174-86. PubMed ID: 26845114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status.
    Bronte G; Franchina T; Alù M; Sortino G; Celesia C; Passiglia F; Savio G; Laudani A; Russo A; Picone A; Rizzo S; De Tursi M; Gambale E; Bazan V; Natoli C; Blasi L; Adamo V; Russo A
    Oncotarget; 2016 Jun; 7(24):35803-35812. PubMed ID: 26993607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Liu ZL; Zhu WR; Zhou WC; Ying HF; Zheng L; Guo YB; Chen JX; Shen XH
    J Integr Med; 2014 Jul; 12(4):346-58. PubMed ID: 25074884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Precision treatment after resistance to first-generation EGFR-TKI in patients with non-small cell lung cancer].
    Pi C; Zhang YC; Xu CR; Zhou Q
    Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):94-97. PubMed ID: 28219202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience.
    Kato Y; Hotta K; Takigawa N; Nogami N; Kozuki T; Sato A; Ichihara E; Kudo K; Oze I; Tabata M; Shinkai T; Tanimoto M; Kiura K
    Cancer Chemother Pharmacol; 2014 May; 73(5):943-50. PubMed ID: 24633759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Factors affecting the sensitivity of EGFR-TKI treatment in advanced non-small cell lung cancer].
    Zhao LD; Li JL; Wang Y; Wang B; Wang HY; Hao XZ; Cui CX; Zhang XR; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2011 Mar; 33(3):217-21. PubMed ID: 21575523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
    Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erratum to
    Editorial Office
    Transl Lung Cancer Res; 2022 Nov; 11(11):2358-2359. PubMed ID: 36519014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD147-mediated glucose metabolic regulation contributes to the predictive role of
    Li X; Fu Q; Zhu Y; Wang J; Liu J; Yu X; Xu W
    Mol Carcinog; 2019 Feb; 58(2):247-257. PubMed ID: 30320488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Research Progress of Mechanisms on Intracranial Metastasis of Non-small Cell Lung Cancer after Clinical Benefit from EGFR-TKI].
    Jiang J; Hu C
    Zhongguo Fei Ai Za Zhi; 2015 Aug; 18(8):518-22. PubMed ID: 26302350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study.
    Yang W; Gao Y; Li X; Zhang J; Liu T; Feng X; Pan H; Yang X; Xie S; Feng X; Lv Z; Wang Y; Chen Z; He J
    World J Surg Oncol; 2017 Nov; 15(1):197. PubMed ID: 29110716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.